Semaglutide Weight Management and Cardiovascular Risk Reduction
ONWARDS 1 compared insulin icodec with insulin glargine U100
in people with T2D initiating basal insulin
R
1:1
ONWARDS 1 enrolled 984 patients with Type 2 Diabetes
Once-weekly insulin icodec
± non-insulin anti-diabetic drugs
Once-daily insulin glargine U100
± non-insulin anti-diabetic drugs
Main phase
Objective:
To confirm the efficacy and safety of once-weekly insulin icodec in
insulin-naïve patients with type 2 diabetes
Primary endpoint:
•
Change in HbA1c from baseline to week 52
Extension phase:
A 26-week extension included in the trial design to assess long-term
safety in people with T2D
Inclusion criteria:
+
52
Extension
weeks
phase
78
weeks
•
T2D treated with OADs* ± GLP-1 RA s.C.
•
Age ≥18 years
·
HbA1c
7-11%
*Pre-trial all OADS including oral GLP-1s are allowed but SU and glinides are to be discontinued at randomisation
T2D: Type 2 diabetes; R: Randomisation; OAD: Oral anti Diabetics; s.c.: subcutaneous; BMI: Body mass index; GLP-1: Glucagon-like peptide-1
BMI ≤40 kg/m2View entire presentation